EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition

Alexander M Cao Zhang iD, Efthymios Ziogos, Tarek Harb, Gary Gerstenblith, Thorsten M Leucker

European Journal of Clinical Investigation · 2024

DOI: 10.1111/eci.14272 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Alexander M Cao Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: PCSK9 Inhibitors, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 87 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have emerged as a novel class of drugs with cardioprotective effects through their lipid‐lowering effects.

Objective

This review aims to discuss existing and novel strategies of PCSK9 inhibition, providing an overview of established randomized controlled trials and ongoing outcome trials that assess the efficacy and long‐term safety of PCSK9 inhibitors. It also explores the evolving role of PCSK9 beyond lipid metabolism and outlines the pleiotropic actions of PCSK9 inhibition in various disorders and future directions including novel strategies to target PCSK9.

Conclusion

PCSK9 inhibition shows promise not only in lipid metabolism but also in other disease processes, including atherosclerotic plaque remodeling, acute coronary syndrome, stroke, inflammation, and immune response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PCSK9 InhibitorsAntibodies, Monoclonal, HumanizedHumansAnticholesteremic AgentsAcute Coronary SyndromeAntibodies, MonoclonalRandomized Controlled Trials as TopicLipid MetabolismStrokePlaque, AtheroscleroticProprotein Convertase 9Cardiovascular DiseasesInflammation

Stichwörter der Autor:innen

PCSK9 inhibitionacute coronary syndromeextra‐coronary ASCVDinflammationlipid metabolismliver disease

Substanzen

PCSK9 InhibitorsPCSK9 protein, humanAntibodies, Monoclonal, HumanizedevolocumabAnticholesteremic AgentsalirocumabAntibodies, MonoclonalProprotein Convertase 9bococizumab

Autor:innen und Institutionen

  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Division of Cardiology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.

ORCID-Profile: Alexander M Cao Zhang

Zitieren

APA

Cao Zhang, A. M., Ziogos, E., Harb, T., Gerstenblith, G., & Leucker, T. M. (2024). Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14272

Vancouver

Cao Zhang AM, Ziogos E, Harb T, Gerstenblith G, Leucker TM. Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14272

BibTeX
@article{CaoZhang2024,
  author = {Cao Zhang, Alexander M and Ziogos, Efthymios and Harb, Tarek and Gerstenblith, Gary and Leucker, Thorsten M},
  title = {Emerging clinical role of proprotein convertase subtilisin/kexin type 9 inhibition–Part two: Current and emerging concepts in the clinical use of PCSK9 inhibition},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1111/eci.14272}
}
Kostenlos starten →